Evidence map›Paper›PMID 29165618›Full record

ArticleMolecular biology and evolution2018

Human-Specific Mutations and Positively Selected Sites in MARCO Confer Functional Changes.

Kyle E Novakowski, Nicholas V L Yap, Charles Yin, Kaori Sakamoto, Bryan Heit, G Brian Golding, Dawn M E Bowdish

Open access · bronzeAbstract read
In one paragraph

Article in Molecular biology and evolution, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Investigating human lung resilience, its evolutionary history and its relation to COPD.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  2. Article
  3. Macrophages: sentinels, warriors, and healers.Human molecular genetics · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kyle E NovakowskiDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Nicholas V L YapDepartment of Biology, McMaster University, Hamilton, ON, Canada.
Charles YinDepartment of Microbiology and Immunology and The Centre for Human Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
Kaori SakamotoDepartment of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA.
Bryan HeitDepartment of Microbiology and Immunology and The Centre for Human Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
G Brian GoldingDepartment of Biology, McMaster University, Hamilton, ON, Canada.
Dawn M E BowdishDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
McMaster University · CAWestern University · CAUniversity of Georgia · US

Funding

Role of MARCO in susceptibility and resistance to tuberculosisR15AI094436 · NIAID · UNIVERSITY OF GEORGIA · PI SAKAMOTO, KAORI · 2012 to 2012
$405k
CIHR MOP-123419NIAID NIH HHS R15 AI094436
6 · The paper itself

Abstract

Macrophage Receptor with COllagenous structure (MARCO) is a class A scavenger receptor that binds, phagocytoses, and modifies inflammatory responses to bacterial pathogens. Multiple candidate gene approach studies have shown that polymorphisms in MARCO are associated with susceptibility or resistance to Mycobacterium tuberculosis infection, but how these variants alter function is not known. To complement candidate gene approach studies, we previously used phylogenetic analyses to identify a residue, glutamine 452 (Q452), within the ligand-binding Scavenger Receptor Cysteine Rich domain as undergoing positive selection in humans. Herein, we show that Q452 is found in Denisovans, Neanderthals, and extant humans, but all other nonprimate, terrestrial, and aquatic mammals possess an aspartic acid (D452) residue. Further analysis of hominoid sequences of MARCO identified an additional human-specific mutation, phenylalanine 282 (F282), within the collagenous domain. We show that residue 282 is polymorphic in humans, but only 17% of individuals (rs6761637) possess the ancestral serine residue at position 282. We show that rs6761637 is in linkage disequilibrium with MARCO polymorphisms that have been previously linked to susceptibility to pulmonary tuberculosis. To assess the functional importance of sites Q452 and F282 in humans, we cloned the ancestral residues and loss-of-function mutations and investigated the role of these residues in binding and internalizing polystyrene microspheres and Escherichia coli. Herein, we show that the residues at sites 452 and 282 enhance receptor function.

Indexed as

Selection, GeneticAnimalsHEK293 CellsHumansMutationPhagocytosisReceptors, ImmunologicMARCO protein, humanReceptors, Immunologichost–pathogen interactionsMARCOpositive selectionscavenger receptorsingle nucleotide polymorphism

Identifiers

PMID29165618
PMCPMC5850514
OpenAlexW2769031876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.